背景:成纤维细胞生长因子21(FGF21)是治疗代谢紊乱疾病的有希望的候选药物,并已用于II期临床试验。目前,代谢性疾病在世界范围内普遍存在,强调了FGF21的巨大市场潜力。因此,必须有效提高FGF21的产量,以满足市场需求。
结果:这里,为了研究载体和宿主细胞对FGF21表达的影响,我们成功地改造了表现出高产率的FGF21菌株。令人惊讶的是,数据显示,具有不同拷贝数的载体显著影响FGF21的表达,并且结果显示表达水平增加4.35倍。此外,双启动子和串联基因表达构建设计的性能优于常规构建方法,最大差异为2.67倍。
结论:通过探索工程载体和宿主细胞,成功实现了FGF21菌株的高产生产。这一突破为FGF21未来的产业化奠定了坚实的基础。此外,FGF21可以很容易地,快速有效地表达,为更多重组蛋白的研究和应用提供更好的工具和平台。
BACKGROUND: Fibroblast growth factor 21 (FGF21) is a promising candidate for treating metabolic disorder diseases and has been used in phase II clinical trials. Currently, metabolic diseases are prevalent worldwide, underscoring the significant market potential of FGF21. Therefore, the production of FGF21 must be effectively improved to meet market demand.
RESULTS: Herein, to investigate the impact of vectors and host cells on FGF21 expression, we successfully engineered strains that exhibit a high yield of FGF21. Surprisingly, the data revealed that vectors with various copy numbers significantly impact the expression of FGF21, and the results showed a 4.35-fold increase in expression levels. Furthermore, the performance of the double promoter and tandem gene expression construction design surpassed that of the conventional construction method, with a maximum difference of 2.67 times.
CONCLUSIONS: By exploring engineered vectors and host cells, we successfully achieved high-yield production of the FGF21 strain. This breakthrough lays a solid foundation for the future industrialization of FGF21. Additionally, FGF21 can be easily, quickly and efficiently expressed, providing a better tool and platform for the research and application of more recombinant proteins.